As the broader market rallied on Tuesday on the back of hopeful rhetoric around tax reform, the healthcare sector happily participated. The biotechnology subgroup of stocks also flocked higher, leaving plenty of so-called “bullish reversals” …
Celgene Corporation's (NASDAQ:CELG) stock were down more than 5% in premarket trade following news of a drug development disappointment. In after-hours on Thursday, the pharmaceutical firm announced it would not take a …
Shares of the Celgene Corporation rose 5.9 percent yesterday after regulators approved the company's Revlimid capsule for a rare blood cancer, a treatment that will cost pharmacies $215 to $225 a pill. The Food and Drug Administration …
If you're looking for a smart stock to buy right now, look no further than Celgene (NASDAQ: CELG). The big biotech has hit a rough patch lately, with a major clinical setback, missing third-quarter revenue expectations, and lowering its full …
The offer of $87 per share for the 90 percent of Juno that Celgene does not own sent Juno's stock soaring 27 percent to $86.31 in premarket trading. Shares of Celgene fell 1 percent to $101.60. The two companies said the deal, agreed by …
Biotech stocks and the related ETFs have been the star performers this year despite some temporary glitches and …
SUMMIT, N.J. (AP) — Biopharmaceutical company Celgene is buying the remainder of Juno Therapeutics Inc. that it doesn't already own in a deal valued at about $9 billion, which will help it develop medicines for patients with incurable …
Celgene is under increasing pressure to replace revenue from its top-selling cancer treatment before copycat medicines eat into Revlimid sales. Its stock lost more than a quarter of its value during a five-day stretch in October after a highly …